Oct 28, 2026 earnings call — Commercial momentum and margin improvement
Revenue just over $2 billion; adjusted EBITDA $337 million and adjusted EPS $2.66, with narrower 2026 guidance and stronger bookings.
Revenue $2.0B (est $2.0B) · EPS $2.66 (est $2.62)
Key quotes
"Consequently, net business wins were a record $3.15 billion up 51% year-over-year, yielding a net book to bill of 1.56x."
"Study startup throughput, a key indicator of impending clinical, activity, grew about 30% year to date, enabled by a range of agentic capabilities."
"This strong execution translated into strong cash generation $300 million of free cash flow generated in the quarter, supporting the repurchase of $400 million of shares and a cash balance of $800 million at quarter end."
Analyst Q&A 14
Direct fee revenue recovery timing
Q (Eric Coldwell · Baird): When will direct fee revenue return to stable growth and what incremental margin can be expected early in recovery?
A: Management said Q3 shows early evidence of margin improvement and that improvements in business mix and cost control are already increasing gross margin and EBITDA. They stressed it takes time for bookings to flow into the P&L and that execution will determine actual results next year.
"So yes, look, I think you can start to see the evidence of this in our Q3 results, Eric." — Nigel Clerkin (CFO)
Booking composition and pass-throughs
Q (David Windley · Jefferies): What drives the strong bookings and why are many awards accompanied by high pass-throughs? How should we expect these to convert to revenue?
A: Management said trailing 12-month direct-fee book-to-bill is 1.3 and that the prior 12-months nearer 1.0 blends into how revenue will build. They explained most bookings scale comes from full service, that many recent wins include high pass-throughs, and that their conservative FSP booking policy affects comparability.
"With the book to bill strength, is driven primarily in any given quarter, just given the relative scale of the business units and the bookings policy by full service." — Barry Balfe (CEO)
Demand environment and funnel
Q (Justin Bowers · DB): Is the demand environment robust across segments and how is the FSP/FSO mix developing?
A: Management said demand is robust, especially in large pharma FSO, and noted strength in labs, evidence generation, and partnerships. They said FSP has developed well, FSO bookings have improved, and they are engaging more biotech targets and converting more partnerships.
"In terms of the demand environment, it remains really robust, at least for us, in large pharma FSO, which I am not sure everybody expected 18, 24 months ago." — Barry Balfe (CEO)
Pricing and outcome-based contracts
Q (Charles Rhyee · TD Cowen): Is the market shifting to outcome/expertise pricing and will AI change how contracts are structured?
A: Management said discussions about rates continue but the bigger opportunity is contracting around results, speed, and predictability rather than hourly rates. They prefer conversations on efficiency and gain-share in partnerships, and customers making progress are those embracing that model.
"So let me drill down to what I think the key points are." — Barry Balfe (CEO)
Economics and cancellations
Q (Elizabeth Anderson · Evercore): Are economics similar like-for-like and should cancellations be modeled at the current run rate?
A: Management said cancellations appear in line with a normal 5 to 6 level and they see no change on that line. They added economics are evolving as ways of working change, and customers are choosing providers who deliver value now while partnering on transformation.
"I do not think there is much to see on the cancellations line, Elizabeth." — Barry Balfe (CEO)
Net interest expense and AI investment
Q (Michael Cherny · Leerink Partners): Can you confirm net interest and how much AI investment offsets pricing pressure?
A: Management confirmed net interest non-GAAP in the quarter was $43 million. Barry was invited to comment on AI and pricing but the explicit numeric link of AI spend to EBITDA was not given in this exchange.
"So yes, net interest expense non GAAP in the quarter, was $43 million" — Nigel Clerkin (CFO)
Margin progress and outlook
Q (Ann Hynes · Mizuho): Are margins tracking ahead and is the mid-16.5% EBITDA range still on track? Any major headwinds or tailwinds for 2027?
A: Management said margin improvements were expected from business mix and operating cost control and that reported margin percent depends partly on pass-throughs. They reiterated the full-year EBITDA margin expectation around 16% to 16.5% remains on track, with fourth-quarter pass-through activity a key driver.
"The reported margin percent, we have also said consistently, does depend on the degree of pass through revenues to some degree as well, obviously." — Nigel Clerkin (CFO)
Guidance metrics and SG&A run rate
Q (Jailendra Singh · Truist): Will you guide to EBITDA next year and how should we model Q3 SG&A run rate given expected increases?
A: Management said they are considering the guidance framework for next year and will provide more with Q4 results. They confirmed they had expected SG&A to increase in Q3 but strong cost control and phasing kept it flat, and they expect SG&A to increase in Q4.
"To that point, on your second question, yes, we did anticipate or we did say that we thought SG&A would increase in Q3." — Nigel Clerkin (CFO)
M&A appetite and capital allocation
Q (UBS): Given business improvement, what is appetite for bolt-on or larger M&A?
A: Management said their capital allocation is balanced across buybacks, organic investment, and selective M&A when timing, valuation, and strategic fit are right. They said they are not pursuing transformational billion-dollar deals and would focus on strategic, high-growth, or high-margin targets that increase their right to win.
"The appetite, indeed the priority, is for a balanced approach to capital allocation." — Barry Balfe (CEO)
Direct fee book-to-bill disclosure
Q (Luke Sergott · Barclays): What was the Q3 direct fee book-to-bill and why change disclosure?
A: Management said the trailing 12-month 1.3x direct fee book-to-bill was highlighted to contrast with the prior 12-month near 1.0 and to help model direct-fee revenue recovery. They said the disclosure aims to give more transparency on booking composition and pacing.
"The reason I focused on a trailing 12-month 1.3x was because it stands in contrast to the preceding 12-month which was closer to 1 flat." — Barry Balfe (CEO)
Gross margin drivers and AI benefits
Q (Jack Meehan · Nephron): What drove the gross margin step-up, can you quantify AI automation benefits, and is pricing flow-through stabilized?
A: Management said gross margin improved as anticipated from business mix and operating cost controls, and that AI delivers both customer-facing capabilities and internal efficiency gains. They emphasized execution and predictability on projects drive realized margin more than initial sold price.
"So look at the no, gross margin progression we saw in the quarter, again, goes back to what we had anticipated." — Nigel Clerkin (CFO)
Narrowed EPS guidance drivers
Q (Sean Dodge · BMO): What changed under the hood to narrow 2026 EPS guidance—debt refinance, interest, buybacks, FX, or other items?
A: Management said two factors were relevant but not massively material and that FX became a bigger headwind versus May. They also said underlying operational assumptions remain largely the same and that being further into the year allows them to narrow the guidance range.
"Neither 1 of them massively material to the overall guidance range, but they would have been a factor, each of them in different directions, obviously." — Nigel Clerkin (CFO)
Where AI helps most in trials
Q (William Blair): Which study workflow areas resonate most with customers and how is ICON uniquely positioned to deploy AI?
A: Management said customers value improvements that drive speed, cost reduction, predictability, and shorter cycle times, with study design and study start-up as high-impact areas. They added ICON focuses on targeted, operational bets—improving planning, site interactions, and workflows—and combines subject matter expertise with tech to make humans more effective.
"Anything that will drive speed, will reduce cost, will drive predictability, will drive cycle time reduction is welcome." — Barry Balfe (CEO)
Pass-through level and exit momentum
Q (RBC): Are pass-throughs leveling as a percent of revenue and what visibility exists on underlying growth exiting 2026?
A: Management said the revenue guidance increase was driven by pass-through momentum and that pass-throughs are now in the low thirties, about one third of revenue, which is a reasonable starting point for next year. They reiterated consistent commercial momentum and said with execution mid-single-digit revenue growth next year is a reasonable proposition though they are not yet guiding.
"Pass throughs now, we have touched on this, I think, the previous call, somewhere in the low thirties, approaching 1 third of our revenues approximately." — Nigel Clerkin (CFO)